# Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)

> **NCT03555890** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 72 (actual)

## Conditions studied

- Rhinitis

## Interventions

- **DRUG:** Levocetirizine IRT 5 mg
- **DRUG:** Levocetirizine ODT 5 mg

## Key facts

- **NCT ID:** NCT03555890
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-18
- **Primary completion:** 2018-09-17
- **Final completion:** 2018-09-17
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2020-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03555890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03555890, "Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03555890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*